Nov 15, 2024	Investor presentation, 15 November 2024

Nov 14, 2024	Notification of buy-back - NEU

Nov 14, 2024	Neuren announces A$50m on-market share buy-back program

Nov 07, 2024	Q3 2024 update

Nov 07, 2024	Pause in Trading

Nov 06, 2024	PRV sold for US$150m - Neuren to receive one third

Nov 01, 2024	Updated Share Trading Policy

Oct 28, 2024	Notification of cessation of securities - NEU

Oct 17, 2024	DAYBUE receives marketing authorization in Canada

Oct 07, 2024	NEU continues PMS P3 preparations after positive FDA meeting

Aug 27, 2024	H1 2024 financial results

Aug 27, 2024	Half Yearly Report and Accounts

Aug 19, 2024	Investor roadshow presentation, 19 August 2024

Aug 16, 2024	Change of Director's Interest Notice - J Basile

Aug 09, 2024	NNZ-2591 Angelman top-line results presentation

Aug 09, 2024	Phase 2 trial shows significant improvements in Angelman

Aug 07, 2024	Trading Halt

Aug 07, 2024	Pause in Trading

Aug 07, 2024	Q2 2024 update

Jul 25, 2024	Neuren to participate in upcoming US investor conferences

Jul 19, 2024	Ceasing to be a substantial holder

Jul 19, 2024	Neuren receives Rare Pediatric Disease Designation from FDA

Jul 02, 2024	Final Director's Interest Notice - T Scott

Jun 17, 2024	Application for quotation of securities - NEU

Jun 13, 2024	Change of Director's Interest Notice - J Basile

May 29, 2024	Corporate Presentation, 29 May 2024

May 28, 2024	Results of Meeting

May 28, 2024	AGM Chair Address & CEO Presentation

May 27, 2024	Pitt Hopkins syndrome Phase 2 trial results presentation

May 27, 2024	Phase 2 trial shows significant improvements in Pitt Hopkins

May 23, 2024	Trading Halt

May 16, 2024	Neuren CEO to present at BIO & Jefferies conferences in US

May 15, 2024	Investor presentation, 15 May 2024

May 09, 2024	DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m

May 07, 2024	Notification of cessation of securities - NEU

Apr 26, 2024	Notification of cessation of securities - NEU

Apr 26, 2024	Virtual AGM online guide

Apr 26, 2024	Notice of Annual General Meeting/Proxy Form

Apr 24, 2024	Q1 2024 quarterly activity and cash flow report

Apr 23, 2024	Trofinetide accepted for Priority Review by Health Canada

Apr 23, 2024	Appendix 4G

Apr 23, 2024	2023 Annual Report to shareholders

Apr 08, 2024	Application for quotation of securities - NEU

Mar 12, 2024	Application for quotation of securities - NEU

Feb 29, 2024	2023 Results webinar

Feb 29, 2024	Neuren reports profit of $157 million for 2023

Feb 29, 2024	Appendix 4E and 2023 full year accounts

Feb 29, 2024	Neuren 2023 results investor webinar on 29 February 2024

Feb 28, 2024	DAYBUE net sales US$87.1 million in Q4 2023

Feb 16, 2024	Comment on research report

Feb 16, 2024	Pause in Trading

Feb 08, 2024	Notification regarding unquoted securities - NEU

Feb 01, 2024	Application for quotation of securities - NEU

Jan 31, 2024	Q4 2023 Appendix 4C Cash Flow Report

Jan 31, 2024	Q4 2023 quarterly activity report

Dec 20, 2023	Completion of enrolment in Neuren's Angelman P2 trial

Dec 19, 2023	Application for quotation of securities - NEU

Dec 18, 2023	Investor presentation, 18 December 2023

Dec 18, 2023	P2 trial shows significant improvements in Phelan-McDermid

Dec 14, 2023	Trading Halt

Dec 05, 2023	Neuren completes enrolment in Pitt Hopkins Phase 2 trial

Nov 20, 2023	Comment on media speculation

Nov 13, 2023	Neuren completes Phelan-McDermid syndrome Phase 2 trial

Nov 08, 2023	Investor presentation, 8 November 2023

Nov 03, 2023	DAYBUE net sales US$66.9 million in Q3 2023

Oct 20, 2023	Q3 2023 quarterly activity and cash flow report

Sep 14, 2023	Change of Director's Interest Notice - J Basile

Sep 01, 2023	S&P DJI Announces September 2023 Quarterly Rebalance

Aug 28, 2023	Investor presentation, 28 August 2023

Aug 28, 2023	Neuren reports 2023 half-year profit after tax of $48m

Aug 28, 2023	Half Yearly Report and Accounts

Aug 25, 2023	Notification of half-year results & investor web conference

Jul 31, 2023	Q2 2023 quarterly activity and cash flow report

Jul 27, 2023	Neuren receives US$100m for expanded DAYBUE agreement

Jul 14, 2023	Investor web conference presentation, 14 July 2023

Jul 14, 2023	Neuren and Acadia expand global partnership for trofinetide

Jun 30, 2023	Neuren completes enrolment in Phelan-McDermid Phase 2 trial

Jun 28, 2023	Neuren opens first site in US for Prader-Willi Phase 2 trial

Jun 14, 2023	Change of Director's Interest Notice

Jun 07, 2023	Neuren receives US$40m milestone payment

Jun 05, 2023	Neuren presenting at Jefferies Global Healthcare Conference

May 30, 2023	Results of Meeting

May 30, 2023	AGM Chair Address & CEO Presentation

Apr 28, 2023	Notice of Annual General Meeting/Proxy Form

Apr 28, 2023	Virtual AGM online guide

Apr 28, 2023	Q1 2023 quarterly activity and cash flow report

Apr 27, 2023	Appendix 4G

Apr 27, 2023	2022 Annual Report to shareholders

Apr 18, 2023	DAYBUE (trofinetide) launched in US - Neuren earns US$40m

Mar 27, 2023	Application for quotation of securities - NEU

Mar 14, 2023	Investor Presentation, 14 March 2023

Mar 13, 2023	Notification of investor webinar

Mar 13, 2023	FDA approves Daybue - the first treatment for Rett syndrome

Mar 02, 2023	Initial Director's Interest Notice

Mar 02, 2023	Neuren appoints Joe Basile to board of directors

Mar 01, 2023	Investor presentation, 1 March 2023

Feb 24, 2023	Investor Presentation, 24 February 2023

Feb 24, 2023	Neuren reports 2022 full-year results

Feb 24, 2023	Appendix 4E and 2022 full year accounts

Feb 21, 2023	Application for quotation of securities - NEU

Jan 31, 2023	Q4 2022 quarterly activity and cash flow report

Jan 23, 2023	Prader-Willi syndrome IND for NNZ-2591 approved by FDA

Dec 23, 2022	Neuren submits IND & first patients complete Phase 2 trials

Dec 07, 2022	Becoming a substantial holder

Dec 02, 2022	Ceasing to be a substantial holder

Nov 23, 2022	Change in substantial holding

Oct 27, 2022	Q3 2022 quarterly activity and cash flow report

Oct 20, 2022	Neuren receives US$10 million milestone payment

Sep 14, 2022	Investor presentation, 14 September 2022

Sep 13, 2022	Rett Syndrome NDA accepted for Priority Review by FDA

Aug 24, 2022	Half-year shareholder update

Aug 24, 2022	Half Yearly Report and Accounts

Aug 08, 2022	Investor presentation, 8 August 2022

Aug 08, 2022	Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS

Jul 29, 2022	Quarterly Activities/Appendix 4C Cash Flow Report

Jul 19, 2022	Acadia submits Rett Syndrome New Drug Application to the FDA

Jul 12, 2022	Neuren commences Phase 2 trial of NNZ-2591 in Angelman

Jul 08, 2022	Notification regarding unquoted securities - NEU

Jul 08, 2022	Neuren appoints Chief Medical Officer in United States

May 30, 2022	Results of Meeting

May 30, 2022	AGM Chairman's Address & CEO Presentation

Apr 29, 2022	Quarterly Activities/Appendix 4C Cash Flow Report

Apr 28, 2022	Virtual AGM online guide

Apr 28, 2022	Notice of Annual General Meeting/Proxy Form

Apr 27, 2022	Change in substantial holding

Apr 27, 2022	Appendix 4G

Apr 27, 2022	Annual Report to shareholders

Mar 25, 2022	FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial

Mar 23, 2022	FDA approval for Phelan-McDermid IND and Phase 2 trial

Mar 11, 2022	Ethics approval for Angelman Phase 2 trial in Australia

Feb 25, 2022	Investor presentation 25 Feb 2022

Feb 25, 2022	FDA approval for Angelman IND and Phase 2 trial

Feb 24, 2022	2021 Results - a transformational year for Neuren

Feb 24, 2022	Preliminary Final Report and 2021 Full Year Accounts

Feb 03, 2022	Notification regarding unquoted securities - NEU

Feb 01, 2022	Neuren appoints Vice President, Corporate Development

Jan 31, 2022	Q4 2021 quarterly activity and cash flow report

Dec 10, 2021	Becoming a substantial holder

Dec 07, 2021	Positive topline results from Phase 3 trial in Rett syndrome

Nov 10, 2021	Neuren presenting at Bell Potter Healthcare Conference

Oct 28, 2021	Q3 2021 quarterly activity and cash flow report

Oct 21, 2021	Neuren receives feedback on IND for Phelan-McDermid syndrome

Oct 20, 2021	Change of Director's Interest Notice - D Angus

Oct 11, 2021	US patent to 2034 granted for Neuren's NNZ-2591 in autism

Oct 08, 2021	Change of Director's Interest Notice - J Harry

Oct 08, 2021	Change of Director's Interest Notice - J Pilcher

Oct 08, 2021	Change of Director's Interest Notice - P Davies

Oct 08, 2021	Application for quotation of securities - NEU

Oct 06, 2021	Update - Proposed issue of securities - NEU

Oct 06, 2021	$3.3 million raised from oversubscribed SPP

Oct 01, 2021	Feedback on Angelman IND and submission of Pitt Hopkins IND

Sep 21, 2021	IND application submitted for NNZ-2591 in Phelan-McDermid

Sep 17, 2021	Share Purchase Plan Offer Booklet

Sep 16, 2021	Section 708A Notice

Sep 16, 2021	New patent issued to 2032 for Neuren's trofinetide in Brazil

Sep 16, 2021	Application for quotation of securities - NEU

Sep 13, 2021	Investor Presentation, 13 September 2021

Sep 13, 2021	Proposed issue of securities - NEU

Sep 13, 2021	Placement to accelerate NNZ-2591 across 4 indications

Sep 10, 2021	Notification of investor presentation, 9.00 AEST 13 Sept 21

Sep 09, 2021	Trading Halt

Sep 03, 2021	FDA grants Orphan Drug designation for Prader-Willi syndrome

Sep 01, 2021	Angelman IND and Ethics applications submitted for NNZ-2591

Sep 01, 2021	Trofinetide Rett syndrome clinical trial in girls aged 2-5

Aug 30, 2021	R&D Tax Incentive Advance Overseas Finding Approval

Aug 25, 2021	Half-year shareholder update

Aug 25, 2021	Half Yearly Report and Accounts

Aug 17, 2021	Notification of investor webinar

Aug 05, 2021	Phase 3 enrolment successfully completed, results in Q4 2021

Jul 30, 2021	Q2 2021 quarterly activity and cash flow report

Jun 28, 2021	Change of Director's Interest Notice

Jun 22, 2021	Results of Meeting

Jun 22, 2021	AGM Chairman's Address and CEO Presentation

Jun 16, 2021	Change of Director's Interest Notice

Jun 15, 2021	Investor presentation, 15 June 2021

Jun 15, 2021	Initial Director's Interest Notice

Jun 15, 2021	Neuren CEO Jon Pilcher appointed to board of directors

Jun 10, 2021	Neuren to present at MST Access investor conference

Jun 10, 2021	Update - Annual General Meeting 2021

Jun 01, 2021	Positive FDA meetings enable INDs for three Phase 2 trials

May 21, 2021	Virtual AGM online guide

May 21, 2021	Notice of Annual General Meeting/Proxy Form

Apr 29, 2021	New patent issued to 2032 for Neuren's trofinetide in Canada

Apr 27, 2021	Appendix 4G

Apr 27, 2021	Annual Report to shareholders

Apr 22, 2021	Quarterly report and cash flow statement for Q1 2021

Mar 23, 2021	Investor presentation, 23 March 2021

Mar 10, 2021	Neuren successfully completes manufacturing for Phase 2

Feb 24, 2021	Neuren corporate presentation, 24 February 2021

Feb 24, 2021	Neuren approaching transforming milestones in 2021

Feb 24, 2021	Preliminary Final Report and 2020 full year accounts

Feb 18, 2021	Change of Director's Interest Notice

Feb 17, 2021	Notification of investor briefing webinar

Feb 16, 2021	Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline

Feb 15, 2021	Successful Phase 1 trial for Neuren's NNZ-2591

Jan 29, 2021	Quarterly report and cash flow statement for Q4 2020

Jan 11, 2021	European Commission grants 3 NNZ-2591 Orphan designations

Dec 07, 2020	Notification of investor briefing webinar

Dec 07, 2020	Positive opinion for all 3 Orphan applications in Europe

Nov 19, 2020	Approval received for final stage of NNZ-2591 clinical trial

Oct 29, 2020	Quarterly report and cash flow statement for Q3 2020

Sep 29, 2020	Neuren requests Orphan designations for NNZ-2591 in Europe

Sep 22, 2020	Neuren initiates manufacture of NNZ-2591 for Phase 2 trials

Aug 26, 2020	Half-year Shareholder Update

Aug 26, 2020	Half Yearly Report and Accounts

Aug 18, 2020	Corporate presentation, 18 August 2020

Aug 11, 2020	Change of Director's Interest Notice

Aug 07, 2020	Appendix 2A

Aug 07, 2020	Change of Director's Interest Notice

Aug 05, 2020	Completion of Share Purchase Plan

Jul 30, 2020	Appointment of CFO & Company Secretary

Jul 27, 2020	Q2 2020 Activity Report and Cash Flow Report

Jul 14, 2020	Final share buy-back notice - Appendix 3F

Jul 14, 2020	Announcement of buy-back - Appendix 3C

Jul 14, 2020	Publications and presentations for trofinetide and NNZ-2591

Jul 13, 2020	Appendix 3G

Jul 09, 2020	Share Purchase Plan Offer Booklet

Jul 06, 2020	Section 708A notice

Jul 06, 2020	Appendix 2A

Jul 01, 2020	Electing to receive SPP documents by e-mail

Jun 29, 2020	Results of Meeting

Jun 29, 2020	AGM Chairman's Address and CEO Presentation

Jun 29, 2020	Proposed issue of Securities - NEU

Jun 29, 2020	Neuren successfully completes $20m capital raising

Jun 25, 2020	Trading Halt

Jun 16, 2020	Temporary enrolment pause ended in Phase 3 trial in the US

Jun 02, 2020	Change of Director's Interest Notice

Jun 01, 2020	Change of Director's Interest Notice

May 29, 2020	Final Director's Interest Notice

May 28, 2020	Virtual AGM online guide

May 28, 2020	Notice of Annual General Meeting/Proxy Form

May 27, 2020	Neuren announces changes to leadership team

May 07, 2020	Neuren commences first clinical trial for NNZ-2591

Apr 29, 2020	Appendix 4G

Apr 29, 2020	Annual Report 2019

Apr 17, 2020	Appendix 4C - quarterly

Apr 17, 2020	Q1 2020 Activity Report

Apr 06, 2020	Corporate presentation, 6 April 2020

Apr 02, 2020	First patent in Israel granted for trofinetide

Mar 26, 2020	Change of Director's Interest Notice

Mar 26, 2020	International institution acquires 14% of Neuren

Mar 24, 2020	Change of Director's Interest Notice

Mar 24, 2020	Temporary pause in new enrolments for LAVENDER trial in US

Mar 20, 2020	Trading Halt

Mar 17, 2020	Neuren to capture substantially greater value after Phase 3

Mar 10, 2020	Additional information

Mar 06, 2020	Compelling results for 2591 dose ranging study in PMS model

Mar 04, 2020	Commentary on potential benefit to Neuren of RPD designation

Mar 04, 2020	Rare Pediatric Disease designation received from FDA

Feb 26, 2020	5 Orphan Drug programs and Rett in Phase 3 funded by partner

Feb 26, 2020	Appendix 4E and 2019 full year accounts

Feb 19, 2020	Update on trofinetide Phase 3 trial in Rett syndrome

Jan 28, 2020	Appendix 4C - quarterly

Dec 12, 2019	2019 year-end update and 2020 outlook

Dec 03, 2019	Patent to 2034 granted in Europe for Neuren's NNZ-2591

Oct 31, 2019	Phase 3 trial of trofinetide in Rett syndrome commences

Oct 18, 2019	Neuren Corporate Presentation, October 2019

Oct 17, 2019	Appendix 4C - quarterly

Oct 16, 2019	FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins

Oct 16, 2019	Pause in Trading

Oct 11, 2019	FDA grants Orphan Drug Designation for NNZ-2591 in Angelman

Sep 20, 2019	Neuren approaching key milestones in Q4 2019

Aug 28, 2019	Neuren advances pipeline for neurodevelopmental disorders

Aug 28, 2019	Half Yearly Report and Accounts

Aug 16, 2019	New patent granted for Neuren's NNZ-2591 in Japan

Jul 31, 2019	Appendix 4C - quarterly

Jul 29, 2019	Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA

Jul 16, 2019	Neuren receives final payment from Lanstead Capital

May 28, 2019	Results of Meeting

May 28, 2019	Chairman's Address at 2019 Annual Meeting of Shareholders

May 17, 2019	Validation for NNZ-2591 neurodevelopmental disorder pipeline

May 17, 2019	NNZ-2591 positive effects in Pitt Hopkins syndrome model

May 17, 2019	NNZ-2591 positive effects in Angelman syndrome model

Apr 30, 2019	Appendix 4C - quarterly

Apr 29, 2019	Notice of Annual General Meeting/Proxy Form

Apr 26, 2019	Appendix 4G

Apr 26, 2019	Annual Report to shareholders

Apr 26, 2019	Update on development plan for NNZ-2591

Mar 28, 2019	Neuren's Rett syndrome Phase 2 trial published in Neurology

Feb 27, 2019	Fundamentals strong as Neuren advances neuroscience pipeline

Feb 27, 2019	Preliminary Final Report and statutory accounts

Feb 18, 2019	NNZ-2591 positive effects in Phelan-McDermid syndrome model

Feb 04, 2019	Plans for Phase 3 trial in Rett syndrome

Feb 01, 2019	Neuren retains ex-North America, appoints investment bank

Jan 31, 2019	Appendix 4C - quarterly

Jan 03, 2019	Final Director's Interest Notice

Dec 31, 2018	Ceasing to be a substantial holder

Dec 18, 2018	2018 Year-end Business Update

Dec 17, 2018	Larry Glass to retire as a director and continue as CSO

Nov 02, 2018	Presentation at AusBiotech Invest and Partnering 2018

Oct 31, 2018	Appendix 4C - quarterly

Oct 26, 2018	Trofinetide ex-North America exclusive negotiation period

Oct 17, 2018	Neuren and ACADIA hold Rett syndrome SAB meeting

Oct 01, 2018	Change of Director's Interest Notice

Sep 21, 2018	FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID

Sep 06, 2018	Investor presentation, 6 September 2018

Aug 31, 2018	Half Yearly Report and Accounts

Aug 29, 2018	Neuren and Lanstead agree to pause settlements for 120 days

Aug 22, 2018	Appointment of auditor

Aug 22, 2018	Neuren receives initial payment of US$10 million from ACADIA

Aug 16, 2018	Change of Director's Interest Notice

Aug 15, 2018	Change of Director's Interest Notice

Aug 07, 2018	Investor update

Aug 07, 2018	Neuren and ACADIA announce agreement for North America

Jul 31, 2018	Appendix 4C - quarterly

Jul 09, 2018	Initial Director's Interest Notice

Jul 05, 2018	Initial Director's Interest Notice

Jul 05, 2018	Initial Director's Interest Notice

Jul 04, 2018	Neuren announces new appointments to the board of directors

Jun 18, 2018	Results of Meeting

Jun 18, 2018	Chairman's Address at 2018 Annual Shareholders' Meeting

May 30, 2018	Change of Director's Interest Notice

May 30, 2018	Final share buy-back notice - Appendix 3F

May 30, 2018	Announcement of buy-back - Appendix 3C

May 23, 2018	Notice under section 708A(5)(e) of the Corporations Act

May 23, 2018	Appendix 3B

May 21, 2018	Neuren announces investment and exclusive negotiation period

May 14, 2018	Notice of Annual General Meeting/Proxy Form

May 08, 2018	Appendix 4G

May 08, 2018	Annual Report to shareholders

Apr 30, 2018	Appendix 4C - quarterly

Apr 30, 2018	First patent in Japan granted for Neuren's trofinetide

Mar 29, 2018	Full Year Statutory Accounts

Mar 29, 2018	Disclosure under Listing Rule 4.3D

Feb 28, 2018	Preliminary Final Report

Jan 30, 2018	Appendix 4C - quarterly

Dec 29, 2017	Final Director's Interest Notice

Dec 29, 2017	Non-executive director retirement

Dec 27, 2017	Change in substantial holding

Dec 05, 2017	Neuren announces new US patent to be granted for NNZ-2591

Nov 16, 2017	Consolidation/Split - NEU

Nov 16, 2017	Notification under Listing Rule 7.20 of share reorganisation

Oct 26, 2017	Appendix 4C - quarterly

Oct 13, 2017	Neuren FDA meeting confirms Phase 3 plan for Rett syndrome

Oct 06, 2017	Investor presentation, 6 October 2017

Oct 05, 2017	Presentations and publication for Rett syndrome trials

Aug 30, 2017	Change of Director's Interest Notice

Aug 30, 2017	Change of Director's Interest Notice

Aug 30, 2017	Change of Director's Interest Notice

Aug 29, 2017	Notice under section 708A(5)(e) of the Corporations Act

Aug 29, 2017	Appendix 3B

Aug 29, 2017	Results of Meeting

Aug 24, 2017	Neuren reports 2017 half-year results

Aug 24, 2017	Half Yearly Report and Accounts

Aug 14, 2017	Notice of special meeting of shareholders

Jul 27, 2017	Appendix 4C - quarterly

Jul 21, 2017	Becoming a substantial holder

Jul 20, 2017	Neuren granted Type B Meeting with FDA for Rett syndrome

Jul 19, 2017	Notice under section 708A(5)(e) of the Corporations Act

Jul 19, 2017	Appendix 3B

Jul 13, 2017	Notice under section 708A(5)(e) of the Corporations Act

Jul 13, 2017	Appendix 3B

Jun 29, 2017	Results of Meeting

Jun 29, 2017	2017 AGM Chairman's Address

Jun 29, 2017	Neuren secures funding for key activities for Rett syndrome

Jun 28, 2017	Response to ASX Price Query

Jun 27, 2017	Trading Halt

Jun 02, 2017	Investor presentation, 2 June 2017

May 31, 2017	Neuren announces grant of two new patents to 2032

May 29, 2017	Notice of Annual General Meeting/Proxy Form

May 08, 2017	Response to Appendix 4C Query

Apr 28, 2017	Appendix 4C - quarterly

Apr 28, 2017	Appendix 4G

Apr 28, 2017	Annual Report to shareholders

Apr 04, 2017	Neuren receives $1 million R&D Tax Incentive

Apr 03, 2017	Investor presentation, 3 April 2017

Mar 30, 2017	Full Year Statutory Accounts

Mar 22, 2017	Trofinetide significant clinical benefit in Rett syndrome

Mar 17, 2017	Trading Halt

Feb 23, 2017	Preliminary Final Report

Feb 02, 2017	Investor presentation, 2 February 2017

Jan 31, 2017	Appendix 4C - quarterly

Jan 30, 2017	Neuren completes Phase 2 trial in pediatric Rett syndrome

Dec 06, 2016	Results of Meeting

Nov 25, 2016	Investor presentation, 25 November 2016

Nov 14, 2016	Notice of special meeting of shareholders

Nov 14, 2016	Neuren completes enrolment in Rett syndrome Phase 2 trial

Oct 31, 2016	Appendix 4C - quarterly

Oct 28, 2016	Neuren receives $0.9m from exercise of last expiring options

Oct 28, 2016	Appendix 3B

Aug 31, 2016	Change of Director's Interest Notice

Aug 31, 2016	Appendix 3B

Aug 30, 2016	Half Yearly Report and Accounts

Aug 25, 2016	Neuren expands Phase 2 Rett syndrome pediatric trial

Jul 26, 2016	Appendix 4C - quarterly

Jun 24, 2016	Neuren presents at Rettsyndrome.org 2016 Research Symposium

Jun 22, 2016	Grant of new patent for Autism Spectrum Disorders

May 31, 2016	Results of Meeting

May 31, 2016	Chairman's Address to Shareholders

May 16, 2016	Change of Director's Interest Notice

May 13, 2016	Presentation at 6th Annual TBI Conference, Washington DC

May 02, 2016	Notice of Annual General Meeting/Proxy Form

Apr 29, 2016	Appendix 4C - quarterly

Apr 26, 2016	Neuren Shareholder Update

Apr 26, 2016	Results of Phase 2 trial in moderate to severe TBI

Apr 22, 2016	Trading Halt

Apr 18, 2016	Appendix 4G

Apr 18, 2016	Annual Report to shareholders

Apr 07, 2016	First subject commences Neuren's Rett syndrome Phase 2 trial

Feb 25, 2016	Neuren reports 2015 full-year financial results

Feb 25, 2016	Appendix 4E and Financial Report 31 December 2015

Jan 29, 2016	Appendix 4C - quarterly

Jan 11, 2016	Neuren Investor Presentation, 11 January 2016

Jan 04, 2016	Neuren Shareholder Update, January 2016

Dec 30, 2015	Appendix 3B

Dec 07, 2015	Trofinetide successful in Phase 2 trial in Fragile X

Dec 03, 2015	Trading Halt

Nov 30, 2015	Grant of composition patent in Europe for Neuren's NNZ-2591

Nov 17, 2015	Corporations Act Notice

Nov 17, 2015	Appendix 3B

Nov 09, 2015	Shareholders provide further support for Rett syndrome

Oct 29, 2015	Neuren completes enrolment in INTREPID clinical trial

Oct 21, 2015	Appendix 4C - quarterly

Oct 13, 2015	IRSF confirms financial support for Neuren's clinical trials

Oct 12, 2015	New US patent covering use of trofinetide for Rett syndrome

Sep 29, 2015	Neuren provides update on Fragile X and INTREPID trials

Aug 25, 2015	Half Yearly Report and Accounts 30 June 2015

Aug 14, 2015	trofinetide confirmed as INN for Neuren's NNZ-2566

Aug 13, 2015	Neuren confirms orphan drug designations in Europe

Jul 31, 2015	Investor presentation, 31 July 2015

Jul 30, 2015	Appendix 4C - quarterly

Jul 29, 2015	Neuren reports progress in orphan drug programs

Jun 01, 2015	Appendix 3B

May 07, 2015	Appendix 3B

Apr 28, 2015	Results of Meeting

Apr 28, 2015	Chairman's Address to Shareholders

Apr 22, 2015	Appendix 3B

Apr 21, 2015	Appendix 4C - quarterly

Mar 26, 2015	Appendix 3B

Mar 25, 2015	Notice of Annual General Meeting/Proxy Form

Mar 25, 2015	Annual Report to shareholders

Mar 02, 2015	Neuren receives response to request for Breakthrough Therapy

Feb 25, 2015	Neuren reports 2014 full-year financial results

Feb 25, 2015	Preliminary Final Report and 2014 full year accounts

Feb 16, 2015	FDA grants Neuren Orphan Drug designation for Rett syndrome

Feb 06, 2015	Appendix 3B

Feb 05, 2015	Change of Director's Interest Notice

Jan 29, 2015	Updated Share Trading Policy

Jan 28, 2015	Neuren announces trofinetide as proposed INN for NNZ-2566

Jan 27, 2015	Appendix 3B

Jan 22, 2015	Appendix 4C - quarterly

Jan 08, 2015	Investor Presentation, 8 January 2015

Jan 05, 2015	Response to ASX Price Query

Dec 30, 2014	Neuren submits Orphan Drug/Breakthrough Therapy applications

Dec 23, 2014	Appendix 3B

Dec 03, 2014	Appendix 3B

Nov 27, 2014	Investor presentation, 27 November 2014

Nov 20, 2014	Appendix 3B

Nov 12, 2014	Neuren successful in Rett syndrome Phase 2 trial

Nov 10, 2014	Trading Halt

Oct 28, 2014	Appendix 3B

Oct 17, 2014	Appendix 4C - quarterly

Oct 09, 2014	Change of Director's Interest Notice

Oct 09, 2014	Appendix 3B

Sep 24, 2014	Appendix 3B

Sep 24, 2014	Issue of long term incentives

Sep 24, 2014	Neuren to release Rett Syndrome trial results in November

Sep 08, 2014	Enrolment commences in Neuren's Concussion Phase 2 trial

Sep 04, 2014	Investor presentation, 4 September 2014

Aug 29, 2014	Appendix 3B

Aug 28, 2014	Neuren reports 2014 half-year financial results

Aug 28, 2014	Half Yearly Report and Accounts

Aug 15, 2014	Appendix 3B

Aug 12, 2014	Neuren advances NNZ-2591 towards IND application

Jul 22, 2014	Appendix 3B

Jul 18, 2014	Appendix 4C - quarterly

Jul 17, 2014	US$3m increase to US Army grant and INTREPID outlook update

Jul 10, 2014	Neuren receives ethics approval to start Concussion trial

Jun 26, 2014	Neuren completes enrolment in Phase 2 trial in Rett Syndrome

Jun 25, 2014	Appendix 3B

Jun 23, 2014	Neuren appoints CMC expert to leadership team

Jun 04, 2014	Neuren receives new US patent for NNZ-2591

Jun 03, 2014	Appendix 3B

Jun 03, 2014	Appendix 3B

May 30, 2014	Appendix 3B

May 21, 2014	Neuren presents at International Meeting for Autism Research

May 14, 2014	Appendix 3B

Apr 30, 2014	Appendix 4C - quarterly

Apr 30, 2014	Appendix 3B

Apr 30, 2014	AGM Results of Meeting

Apr 30, 2014	Chairman's AGM Address to Shareholders

Apr 02, 2014	Presentation at Morgans Emerging Companies Conference

Mar 27, 2014	Appendix 3B

Mar 27, 2014	Notice of Annual General Meeting/Proxy Form

Mar 27, 2014	Annual Report to shareholders

Feb 27, 2014	Neuren reports financial results for 2013

Feb 27, 2014	Preliminary Final Report and audited Financial Statements

Feb 21, 2014	Appendix 3B

Feb 14, 2014	Appendix 3B

Jan 31, 2014	Appendix 4C - quarterly

Jan 28, 2014	Neuren reports progress in NNZ-2566 clinical trial programs

Jan 15, 2014	Appendix 3B

Jan 02, 2014	Appendix 3B

Nov 29, 2013	Appendix 3B

Nov 27, 2013	Appendix 3B

Nov 27, 2013	Neuren Share Purchase Plan raises $2 million

Nov 20, 2013	Ceasing to be a substantial holder

Nov 19, 2013	Investor presentation, 19 November 2013

Nov 15, 2013	Appendix 3B

Nov 14, 2013	Change in substantial holding

Nov 12, 2013	Appendix 3B

Nov 06, 2013	Change of Director's Interest Notice

Nov 04, 2013	Share Purchase Plan record date

Nov 04, 2013	SPP Certification

Nov 04, 2013	Appendix 3B

Oct 31, 2013	Becoming a substantial holder

Oct 30, 2013	Share Purchase Plan offer documents

Oct 30, 2013	Appendix 4C - quarterly

Oct 30, 2013	Orphan drug designation from FDA for NNZ-2566 in Fragile X

Oct 28, 2013	Section 708A(5)e Notice

Oct 28, 2013	Appendix 3B

Oct 22, 2013	Placement of $21.5m to accelerate execution of strategy

Oct 18, 2013	Neuren receives Fast Track designation for Fragile X

Oct 18, 2013	Trading Halt

Oct 10, 2013	Appendix 3B

Oct 09, 2013	Response to ASX Price Query

Oct 09, 2013	Investor presentation

Oct 01, 2013	Neuren data presented at Fragile X Foundation meeting

Sep 26, 2013	Appendix 3B

Sep 19, 2013	Change of Director's Interest Notice

Sep 11, 2013	Appendix 3B

Sep 09, 2013	Neuren opens new IND for NNZ-2566 in Fragile X Syndrome

Sep 04, 2013	Final Director's Interest Notice

Sep 02, 2013	Neuren announces changes to its leadership team

Aug 29, 2013	Half Yearly Report and Accounts

Aug 05, 2013	Notice under section 708A(5)(e) of the Corporations Act

Aug 05, 2013	Response to social media commentary re Rett trial

Aug 05, 2013	Trading Halt Request

Aug 05, 2013	Trading Halt

Jul 31, 2013	Appendix 4C - quarterly

Jul 30, 2013	Investor presentation July 2013

Jul 30, 2013	Appendix 3B Option Exercise

Jul 29, 2013	Results in Fragile X Model with NNZ 2591

Jul 26, 2013	Response to ASX Price Query

Jul 12, 2013	Neuren receives two new patents

Jul 11, 2013	Notice under section 708A(5)(e) of the Corporations Act

Jul 11, 2013	Appendix 3B Option Exercise amended

Jul 11, 2013	Appendix 3B Option Exercise

Jun 26, 2013	Notice under section 708A(5)(e) of the Corporations Act

Jun 26, 2013	Appendix 3B Option Exercise

Jun 25, 2013	Response to ASX Price Query Letter

Jun 18, 2013	Notice under section 708A(5)(e) of the Corporations Act

Jun 12, 2013	Appendix 3B Option Exercise

Jun 05, 2013	FDA Fast Track granted for NNZ2566 Rett program

May 29, 2013	Change of Director's Interest Notice

May 29, 2013	Appendix 3B Equity Performance Rights

May 29, 2013	Appendix 3B Loan Funded Shares

May 29, 2013	Notice under section 708A(5)(e) of the Corporations Act

May 24, 2013	CFO appointment

May 22, 2013	Final Director's Interest Notice

May 22, 2013	Final Director's Interest Notice

May 22, 2013	Appendix 3B Exercise of Options

May 22, 2013	Lapse of Unlisted Options

May 22, 2013	Change of Director's Interest Notice

May 22, 2013	Change of Director's Interest Notice

May 21, 2013	Investor Presentation May 2013

May 20, 2013	Results of Meeting

May 20, 2013	CEO Presentation to AGM

May 20, 2013	Chairman's Address to AGM

May 15, 2013	Response to ASX Price Query Letter

Apr 30, 2013	Appendix 4C - quarterly

Apr 19, 2013	Notice of Annual General Meeting/Proxy Form

Apr 15, 2013	Shareholder Update

Apr 04, 2013	Ceasing to be a substantial holder

Mar 28, 2013	Annual Report to shareholders

Feb 28, 2013	Preliminary Final Report

Feb 01, 2013	Initial Director's Interest Notice

Jan 31, 2013	Dr Richard Treagus joins Neuren Board

Jan 31, 2013	Appendix 4C - quarterly

Jan 09, 2013	Neuren appoints Nancy Jones SD Clinical & Medical Affairs

Dec 24, 2012	Neuren IND open for Rett Phase II trial

Dec 20, 2012	Appendix 3B

Nov 30, 2012	Neuren TAP Conference presentation and Fragile X results

Nov 22, 2012	Neuren completes Phase I NNZ2566 study/files Phase II IND

Nov 09, 2012	Amended 2 - Change in substantial holding

Nov 09, 2012	Amended Change in substantial holding

Nov 09, 2012	Change in substantial holding

Oct 31, 2012	Appendix 4C - quarterly

Oct 25, 2012	Response to ASX Price Query

Oct 19, 2012	NNZ2566 selected as Windhover Top 10 Neuroscience Project

Aug 30, 2012	Half Yearly Report and Accounts

Aug 09, 2012	Neuren appoints Joe Horrigan VP Clinical and Medical Affairs

Aug 07, 2012	NNZ2566 Rationale in ASDs

Jul 31, 2012	Appendix 4C - quarterly

Jul 06, 2012	Neuren awarded Rett Syndrome trial grant

Jun 08, 2012	Final Director's Interest Notice

Jun 08, 2012	Initial Director's Interest Notice

May 31, 2012	Results of Meeting

May 31, 2012	CEO's address to AGM

May 29, 2012	Neuren announces cancer xenograft testing results

May 25, 2012	Change in substantial holding

May 16, 2012	Rett Syndrome pre-IND meeting held with FDA

May 02, 2012	Notice under section 708A(5)(e) of the Corporations Act

Apr 30, 2012	Appendix 4C - quarterly

Apr 27, 2012	Appendix 3B (exercise of options)

Apr 27, 2012	Notice of Annual General Meeting/Proxy Form

Apr 19, 2012	Response to ASX Price Query

Mar 30, 2012	Neuren 2011 Annual Report

Mar 08, 2012	Initial Director's Interest Notice

Mar 08, 2012	Neuren appoints Bruce Hancox to board of directors

Mar 08, 2012	Neuren presentation to Arrowhead TBI Conference

Feb 29, 2012	Neuren 2011 Preliminary Final Report

Jan 31, 2012	Appendix 4C - quarterly

Dec 22, 2011	Neuren to proceed with oral NNZ2566 trial

Dec 12, 2011	Change in substantial holding

Dec 09, 2011	Response to ASX Price Query

Nov 21, 2011	Neuren Completes Phase II trial Cohort 2

Nov 07, 2011	Appendix 3B (exercise of options)

Nov 03, 2011	Change in substantial holding

Nov 03, 2011	Change in substantial holding

Oct 28, 2011	Appendix 4C - quarterly

Oct 26, 2011	Appendix 3B (amendment)

Oct 26, 2011	Change of Director's Interest Notice

Oct 26, 2011	Change of Director's Interest Notice

Oct 26, 2011	Change of Director's Interest Notice

Oct 26, 2011	Change of Director's Interest Notice

Oct 26, 2011	Change of Director's Interest Notice

Oct 26, 2011	Appendix 3B

Oct 20, 2011	Response to ASX Price Query

Aug 30, 2011	Half Yearly Report and Accounts

Aug 17, 2011	Becoming a substantial holder

Aug 16, 2011	Becoming a substantial holder

Aug 16, 2011	Notice under section 708A(5)(e) of the Corporations Act

Aug 16, 2011	Appendix 3B

Aug 16, 2011	Neuren places $3m of rights issue shortfall

Jul 29, 2011	Appendix 4C - quarterly

Jul 27, 2011	NEU Broker Presentation July 2011

Jul 22, 2011	Neuren CEO presentation to Bioshares Biotech Summit

Jul 21, 2011	Change of Director's Interest Notice

Jul 21, 2011	Change of Director's Interest Notice

Jul 19, 2011	Appendix 3B

Jul 19, 2011	Results of Neuren Rights Issue

Jun 29, 2011	Neuren Confirms Despatch of Rights Issue Offer Documents

Jun 28, 2011	Appendix 3B

Jun 24, 2011	CEO presentation to AusBiotech New York

Jun 20, 2011	Rights Issue Eligible Shareholder Notice

Jun 20, 2011	Change in substantial holding

Jun 15, 2011	Rights Issue Notice to Foreign Shareholders

Jun 15, 2011	Rights Issue Notice to Optionholders

Jun 15, 2011	Rights Issue Notice under Section 708AA

Jun 15, 2011	Appendix 3B (renounceable rights issue)

Jun 15, 2011	Neuren Rights Issue Letter of Offer (Australian residents)

Jun 15, 2011	Neuren Rights Issue Offer Document (NZ residents)

Jun 15, 2011	Neuren announces Renounceable Rights Issue

Jun 06, 2011	Notice under section 708A(5)(e) of the Corporations Act

Jun 06, 2011	Neuren completes placement and converts remaining note

Jun 06, 2011	Appendix 3B (options)

Jun 06, 2011	Appendix 3B (shares)

Jun 03, 2011	Notice under section 708A(5)(e) of the Corporations Act

Jun 03, 2011	Appendix 3B

Jun 02, 2011	Notice under section 708A(5)(e) of the Corporations Act

Jun 02, 2011	Appendix 3B

May 31, 2011	Results of Annual Meeting

May 31, 2011	Results of Special Meeting

May 31, 2011	Neuren CEO Presentation to AGM

May 20, 2011	Neuren reduces outstanding convertible note principal

May 19, 2011	Neuren's Perseis selects lead antibodies

May 13, 2011	Notice of Special Shareholders Meeting/Proxy Form

May 11, 2011	Neuren Completes Phase II trial Cohort 1

May 06, 2011	Notice under section 708A(5)(e) of the Corporations Act

May 06, 2011	Appendix 3B

May 05, 2011	Becoming a substantial holder

May 04, 2011	Neuren Announces Private Placement and Rights Issue

May 02, 2011	Trading Halt

Apr 29, 2011	Notice of Annual General Meeting/Proxy Form

Apr 29, 2011	Appendix 4C - quarterly

Apr 27, 2011	Appendix 3B

Apr 20, 2011	Notice under section 708A(5)(e) of the Corporations Act

Apr 20, 2011	Appendix 3B

Apr 20, 2011	Appendix 3B

Mar 31, 2011	Annual Report to shareholders

Mar 23, 2011	Appendix 3B

Mar 22, 2011	Notice under section 708A(5)(e) of the Corporations Act

Mar 21, 2011	Appendix 3B

Mar 21, 2011	Appendix 3B

Mar 21, 2011	Appendix 3B

Mar 21, 2011	Results of Meeting

Mar 10, 2011	Response to ASX Price Query

Mar 03, 2011	Notice of Special Shareholders Meeting

Feb 28, 2011	Preliminary Final Report

Feb 21, 2011	Appendix 3B

Feb 18, 2011	Notice under section 708A(5)(e) of the Corporations Act

Feb 18, 2011	Appendix 3B

Feb 08, 2011	Lapse of unquoted options

Jan 31, 2011	Appendix 4C - quarterly

Jan 21, 2011	Appendix 3B

Jan 21, 2011	Appendix 3B (amended)

Jan 19, 2011	Notice under section 708A(5)(e) of the Corporations Act

Jan 19, 2011	Appendix 3B

Jan 19, 2011	Appendix 3B

Dec 22, 2010	Appendix 3B

Dec 20, 2010	Notice under section 708A(5)(e) of the Corporations Act

Dec 20, 2010	Securities Trading Policy

Dec 20, 2010	Appendix 3B

Dec 20, 2010	Appendix 3B

Nov 22, 2010	Appendix 3B

Nov 19, 2010	Notice under section 708A(5)(e) of the Corporations Act

Nov 19, 2010	Appendix 3B

Nov 19, 2010	Appendix 3B

Nov 18, 2010	Neuren Initiates NNZ2566 Oral Formulation Development

Nov 16, 2010	Neuren Completes Additional Phase I Study for TBI

Oct 27, 2010	Appendix 4C - quarterly

Oct 27, 2010	Appendix 3B

Oct 20, 2010	Notice under section 708A(5)(e) of the Corporations Act

Oct 20, 2010	Appendix 3B

Oct 20, 2010	Appendix 3B

Oct 07, 2010	Lapse of unquoted options

Sep 23, 2010	Appendix 3B

Sep 21, 2010	Notice under section 708A(5)(e) of the Corporations Act

Sep 21, 2010	Appendix 3B

Sep 21, 2010	Appendix 3B

Aug 26, 2010	Half Yearly Report and Accounts

Aug 25, 2010	Appendix 3B

Aug 20, 2010	Notice under section 708A(5)(e) of the Corporations Act

Aug 20, 2010	Appendix 3B

Aug 20, 2010	Appendix 3B

Jul 28, 2010	Appendix 4C - quarterly

Jul 23, 2010	Appendix 3B

Jul 21, 2010	Notice under section 708A(5)(e) of the Corporations Act

Jul 21, 2010	SpringTree becomes a substantial shareholder

Jul 21, 2010	Appendix 3B

Jul 21, 2010	Appendix 3B

Jun 24, 2010	Appendix 3B

Jun 21, 2010	Notice under section 708A(5)(e) of the Corporations Act

Jun 21, 2010	Appendix 3B (options)

Jun 21, 2010	Appendix 3B (shares)

May 27, 2010	Appendix 3B

May 25, 2010	Results of Meeting

May 25, 2010	CEO Presentation to AGM

May 21, 2010	Notice under section 708A(5)(e) of the Corporations Act

May 21, 2010	Appendix 3B

May 21, 2010	Appendix 3B

May 06, 2010	Neuren Starts Phase II Trial of NNZ2566

Apr 30, 2010	Appendix 4C - quarterly

Apr 27, 2010	Notice of Annual General Meeting/Proxy Form

Apr 23, 2010	Appendix 3B (convertible note)

Apr 21, 2010	Notice under section 708A(5)(e) of the Corporations Act

Apr 21, 2010	Appendix 3B (options)

Apr 21, 2010	Appendix 3B (shares)

Apr 06, 2010	Lapse of unquoted options

Mar 30, 2010	Annual Report to shareholders

Mar 25, 2010	Appendix 3B - ESOP

Mar 24, 2010	Appendix 3B (convertible note)

Mar 22, 2010	Notice under section 708A(5)(e) of the Corporations Act

Mar 22, 2010	Appendix 3B

Mar 22, 2010	Appendix 3B

Mar 19, 2010	Grant funding for TFF oncology program

Mar 03, 2010	Trial of Second Neuren Drug Motiva to be Initiated

Feb 26, 2010	Preliminary Final Report

Feb 22, 2010	Appendix 3B (convertible note)

Feb 18, 2010	Notice under section 708A(5)(e) of the Corporations Act

Feb 18, 2010	Appendix 3B (shares)

Feb 18, 2010	Appendix 3B (options)

Feb 12, 2010	Ceasing to be a substantial holder

Feb 12, 2010	Change in substantial holding

Feb 12, 2010	Change in substantial holding

Feb 12, 2010	Change in substantial holding

Feb 11, 2010	Cato strategic partnership and appoints US CMO

Jan 29, 2010	Appendix 4C - quarterly

Jan 20, 2010	Appendix 3B

Jan 13, 2010	Change in substantial holding

Dec 24, 2009	Change of Director's Interest Notice

Dec 23, 2009	Notice under section 708A(5)(e) of the Corporations Act

Dec 23, 2009	Appendix 3B (options)

Dec 23, 2009	Appendix 3B (shares)

Dec 23, 2009	Neuren Completes Shareholder Approved Funding

Dec 22, 2009	Results of Special Shareholders Meeting

Dec 15, 2009	Initial Director's Interest Notice

Dec 04, 2009	Notice under section 708A(5)(e) of the Corporations Act

Dec 04, 2009	Appendix 3B

Dec 04, 2009	Notice of Special Shareholders Meeting

Nov 25, 2009	Dr John Holaday joins Neuren Board

Nov 18, 2009	Appendix 3B (notes)

Nov 18, 2009	Appendix 3B (options)

Nov 18, 2009	Notice under section 708A(5)(e) of the Corporations Act

Nov 18, 2009	Neuren Arranges up to AU$7.8m in New Funding

Nov 18, 2009	Appendix 3B (shares)

Nov 18, 2009	Reinstatement to Official Quotation

Nov 16, 2009	Suspension from Official Quotation

Nov 12, 2009	Trading Halt

Oct 30, 2009	Appendix 4C - quarterly

Sep 25, 2009	Notice under section 708A(5)(e) of the Corporations Act

Sep 25, 2009	Appendix 3B

Sep 22, 2009	Reponse to Price Query

Aug 31, 2009	Half Year Report and Accounts

Aug 14, 2009	Appendix 3B

Aug 14, 2009	Neuren raises NZ$1 million through SPP

Jul 31, 2009	Appendix 4C - quarterly

Jul 22, 2009	Neuren SPP section 708A notice

Jul 21, 2009	SPP NZ Certification

Jul 20, 2009	Neuren NNZ-2566 Development Overview

Jul 20, 2009	Neuren Share Purchase Plan

Jul 20, 2009	Neuren Chairmans SPP Letter

Jul 15, 2009	SPP terms update

Jul 10, 2009	Neuren Share Purchase Plan

Jul 02, 2009	Ceasing to be a substantial holder

Jul 01, 2009	Neuren obtains further US$14m US Army funding

May 28, 2009	Results of Meeting

May 28, 2009	Presentation to AGM

May 28, 2009	Chairman's Address to Shareholders

May 15, 2009	Response to ASX Query - Appendix 4C

Apr 30, 2009	Appendix 4C - quarterly

Apr 28, 2009	Notice of Annual General Meeting/Proxy Form

Apr 22, 2009	Neuren Progresses Cancer Program

Apr 21, 2009	Trading Halt

Apr 17, 2009	Response to ASX Price Query

Apr 16, 2009	Trading Halt

Apr 01, 2009	Lapse of unquoted options

Mar 31, 2009	Annual Report to shareholders

Mar 30, 2009	Final Director's Interest Notice

Feb 27, 2009	Preliminary Final Report

Jan 30, 2009	Appendix 4C - quarterly

Jan 21, 2009	Neuren Strategy Update

Jan 20, 2009	Respone to ASX price query

Jan 19, 2009	Trading Halt

Jan 14, 2009	Change of Director's Interest Notice

Dec 24, 2008	Neuren Announces Glypromate Trial Preliminary Results

Nov 10, 2008	Phase 3 trial data collection completed

Oct 31, 2008	Appendix 4C - quarterly

Sep 30, 2008	Appendix 3B

Sep 30, 2008	Change of Director's Interest Notice

Sep 30, 2008	Change of Director's Interest Notice

Sep 30, 2008	Neuren raises $2m through underwritten SPP

Sep 30, 2008	Appendix 3B

Sep 04, 2008	US Army to provide additional NNZ2566 trial funding

Aug 29, 2008	Half Yearly Report and Accounts

Aug 28, 2008	Results of Special Shareholders' Meeting

Aug 27, 2008	Neuren extends SPP closing date

Aug 27, 2008	Neuren signs cancer license and collaboration agreement

Aug 21, 2008	NZ Securities Act certification for SPP

Aug 15, 2008	Share Purchase Plan letter to eligible shareholders

Aug 15, 2008	Notice under section 708A(5)(e) of the Corporations Act

Aug 12, 2008	Change in substantial holding

Aug 12, 2008	Notice of Special Meeting

Aug 06, 2008	Neuren Share Purchase Plan

Aug 06, 2008	Appendix 3B

Aug 06, 2008	Neuren raises a minimum of $3 million

Aug 06, 2008	Reinstatement to Official Quotation

Aug 04, 2008	Voluntary Suspension extended

Jul 31, 2008	Appendix 4C - quarterly

Jul 31, 2008	Suspension from Official Quotation

Jul 29, 2008	Trading Halt

Jul 21, 2008	Glypromate and NNZ 2566 in Top 10 Neuroscience Projects

Jul 16, 2008	NEU Completes Glypromate Phase 3 Recruitment

Jun 30, 2008	Neuren to get early results from Glypromate trial

May 29, 2008	Results of Meeting

May 29, 2008	CEO presentation to AGM

May 26, 2008	Response to ASX Query re: Appendix 4C

May 15, 2008	Positive interim safety analysis for Glypromate

Apr 30, 2008	Appendix 4C - quarterly

Apr 29, 2008	Quarterly Update to Shareholders April 2008

Apr 29, 2008	Notice of Annual General Meeting/Proxy Form

Mar 31, 2008	Annual Report to shareholders

Mar 18, 2008	Co-CEOs remuneration packages

Feb 29, 2008	Appendix 4E Preliminary Final Report

Feb 26, 2008	Appendix 3B

Feb 18, 2008	Form 604

Feb 13, 2008	Becoming a substantial holder

Feb 11, 2008	Change of Director's Interest Notice

Feb 11, 2008	Change of Director's Interest Notice

Feb 11, 2008	Rights issue raises $7.1m and notes convert

Feb 11, 2008	Substantial shareholder notice

Feb 07, 2008	Change in substantial holding

Feb 07, 2008	Appendix 3B - shares issued on conversion of notes

Feb 07, 2008	Appendix 3B - allotment of rights issue underwriter shares

Feb 05, 2008	Notice under section 708A(5)(e)

Feb 01, 2008	Appendix 3B - allotment of rights issue shares

Jan 31, 2008	Neuren Appendix 4C December 2007

Jan 31, 2008	Results of Rights Issue

Jan 21, 2008	US Department of Defense Approves NNZ2566 Funding

Jan 17, 2008	Glypromate trial recruits 100th patient

Jan 09, 2008	Neuren Confirms Despatch of Rights Issue Offer Documents

Jan 09, 2008	Section 708AA Notice

Dec 19, 2007	Foreign Shareholder Notice re Rights Issue

Dec 19, 2007	Shareholder Notice re Rights Issue

Dec 19, 2007	Optionholder Notice re Rights Issue

Dec 19, 2007	Section 708AA Notice

Dec 19, 2007	Appendix 3B - Non-renounceable Rights Issue

Dec 19, 2007	Rights Issue NZ Investment Statement and Prospectus

Dec 19, 2007	Rights Issue Letter of Offer

Dec 19, 2007	D Clarke Appendix 3Z

Dec 19, 2007	Neuren announces non-renounceable rights issue

Dec 17, 2007	Trading Halt

Dec 04, 2007	Neuren Clinical Development Update

Dec 03, 2007	Neuren Corporate Update December 2007

Nov 12, 2007	Neuren announces reorganisation

Nov 07, 2007	NNZ-2566 successful Phase 1b trial results

Oct 31, 2007	Appendix 4C - quarterly

Oct 16, 2007	Neuren completes acquisition of Hamilton Pharmaceuticals

Oct 16, 2007	Notice under section 708A(5)(e) of the Corporations Act

Oct 16, 2007	Appendix 3B - issue of convertible notes

Oct 16, 2007	Appendix 3B - issue of shares

Oct 12, 2007	Results of Meeting

Sep 27, 2007	Notice of Special Meeting of Shareholders

Sep 26, 2007	Neuren launches Australian Phase 3 Trial Sites

Sep 20, 2007	Neuren completes moderate TBI safety trial

Sep 11, 2007	Change in substantial holding

Sep 07, 2007	NZ arm of Phase 3 trial commences

Aug 31, 2007	Half Yearly Report and Accounts

Aug 23, 2007	Corporate Update Presentation

Jul 31, 2007	Commitments test entity - second quarter

Jul 31, 2007	Acquisition of Motiva through Hamilton Pharmaceuticals

Jul 24, 2007	Lapse of Unquoted Options

Jun 29, 2007	Cambridge University Alliance

May 31, 2007	First patient enters Glypromate Phase 3 trial

May 22, 2007	Revised Constitution

May 22, 2007	2007 AGM Results

May 22, 2007	CEO Presentation AGM

May 14, 2007	Bachem Glypromate Collaboration

May 10, 2007	Clinical Trials Update May 2007

Apr 30, 2007	Commitments Test Entity - First Quarter Report

Apr 24, 2007	Notice of Annual General Meeting

Mar 29, 2007	Annual Report

Mar 20, 2007	Change of Director's Interest Notice

Mar 16, 2007	Substantial Security Holder Notice

Mar 16, 2007	Preliminary Final Report

Feb 26, 2007	Neuren scientist receives Laureate award

Feb 19, 2007	Appendix 3B - ESOP options exercised

Feb 13, 2007	Further Validation of NNZ-2566 as TBI Treatment

Jan 31, 2007	Commitments Test Entity - Fourth Quarter Report

Jan 31, 2007	US FDA approves Phase 3 IND for Glypromate Trial

Jan 29, 2007	Appendix 3B - escrow period ending 3 February 2007

Jan 17, 2007	Appendix 3B

Jan 17, 2007	Successful NNZ-2566 safety trial results

Jan 12, 2007	CEO Presentation to Investors and Partners Jan 2007

Dec 19, 2006	Engages Burrill to progress out-licensing

Dec 05, 2006	Partnering Update Presentation

Nov 03, 2006	Appendix 3B

Nov 03, 2006	Raises $1.6million

Oct 31, 2006	Commitments Test Entity - Third Quarter Report

Oct 23, 2006	Letter to shareholders re SPP extension

Oct 20, 2006	Preclinical results show cancer regression

Oct 17, 2006	Extends SPP

Oct 16, 2006	NNZ 2591 positive memory loss reversal results

Sep 29, 2006	Notice under section 708A(5)(e) of the Corporations Act

Sep 27, 2006	Positive Preclinical Results for NNZ-3006

Sep 22, 2006	Neuren Share Purchase Plan Disclosures

Sep 22, 2006	Update for Shareholders Sept 2006

Sep 19, 2006	Appendix 3B - Placement shares

Sep 19, 2006	A$6.0 million Share placement & Share Purchase Plan

Sep 12, 2006	Half Yearly Report

Sep 04, 2006	Glypromate Phase 2 Trial with US Army

Aug 22, 2006	Glypromate Phase 2 trial final results

Aug 21, 2006	ASX Waiver for reporting results of IFRS transition periods

Aug 14, 2006	Neuren to present NNZ2566 Phase 2 Strategy

Aug 14, 2006	Neuren presentation to US Army conference

Aug 02, 2006	Selects candidate for oral treatment of Parkinsons

Jul 31, 2006	Commitments Test Entity - Second Quarter Report

Jul 21, 2006	Appendix 3B

Jul 18, 2006	Appoints Chief Operating Officer

Jul 11, 2006	Nerve Protection Compounds Research Published

Jun 02, 2006	Change of Director's Interest Notice

Jun 02, 2006	Change of Director's Interest Notice

May 29, 2006	Further US Army results presented on NNZ-2566

May 11, 2006	Granted US patent for NNZ-2566

May 04, 2006	Change of Director's Interest Notice

May 04, 2006	Change of Director's Interest Notice

May 03, 2006	Results of AGM

May 03, 2006	Neuren AGM CEO Presentation

Apr 28, 2006	Commitments Test Entity - First Quarter Report

Apr 26, 2006	Neuren & US Army NNZ 2566 brain seizure results

Apr 26, 2006	CEO Pipeline & Strategy Update

Apr 18, 2006	Becoming a substantial holder

Apr 12, 2006	Reports successful Phase 2 results

Apr 04, 2006	Presentation to US Conferences

Mar 31, 2006	Notice of Annual General Meeting

Mar 31, 2006	Annual Report

Mar 22, 2006	Preclinical results for oral administration of NNZ-2566

Mar 06, 2006	NNZ-2566 Phase 1 trial to commence

Feb 28, 2006	Preliminary Final Report

Feb 07, 2006	Investor Update February 2006

Feb 01, 2006	FDA pre-clinical requirements to Phase 3 completed

Jan 31, 2006	Commitments Test Entity - Fourth Quarter Report

Jan 25, 2006	Appendix 3B End of Restriction Period

Dec 15, 2005	Letter to Shareholders re Share Placement

Dec 02, 2005	Short Form Prospectus

Dec 02, 2005	Capital Raising Presentation November 2005

Dec 02, 2005	Appendix 3B

Dec 02, 2005	Neuren raises $6.4 million in share placement

Dec 02, 2005	Reinstatement to Official Quotation

Dec 01, 2005	Suspension from Official Quotation

Nov 29, 2005	Trading Halt

Nov 24, 2005	Neuren Agreement with Jackson Foundation for Phase 3

Nov 09, 2005	Neuren Senior Scientist inducted to US Institute of Medicine

Oct 31, 2005	Commitments Test Entity - Third Quarter Report

Oct 14, 2005	Presentation Market Update - Oct 2005

Oct 04, 2005	Neuren Wins NZ Biotechnology Co of the Year Award

Oct 03, 2005	Response to ASX Share Price Query

Sep 06, 2005	Parkinsons & Hypertension patents issued

Aug 31, 2005	Half Yearly Report & Half Year Accounts

Aug 30, 2005	Neuren initiates Phase 2 trial

Aug 24, 2005	US Army Presents Neuren Research Results

Aug 08, 2005	Appendix 3B

Jul 29, 2005	Commitments Test Entity - Second Quarter Report

Jul 11, 2005	Walter Reed NNZ-2566 Contract Expanded

Jun 06, 2005	FDA advances Neuren to Phase

May 30, 2005	Results of Annual General Meeting

May 30, 2005	AGM - CEO Presentation

May 20, 2005	Appendix 3B

Apr 29, 2005	Commitments Test Entity - First Quarter Report

Apr 22, 2005	Annual Report 2004 & Notice of AGM

Mar 31, 2005	Annual Report 2004

Mar 17, 2005	Neuren CEO Update March 2005

Mar 15, 2005	Walter Reed Collaboration

Mar 14, 2005	Change of Director's Interest Notice (NZ Disclosure) x2

Mar 14, 2005	Change of Director's Interest Notice x2

Mar 14, 2005	Initial Director's Interest Notice

Mar 14, 2005	Initial Director's Interest Notice

Mar 02, 2005	Neuren & Metabolic NRP Collaboration

Feb 28, 2005	Preliminary Final Report

Feb 09, 2005	Initial Director's Interest Notice x17 (NZ Disclosures)

Feb 09, 2005	Initial Director's Interest Notice x 5

Feb 07, 2005	Former Pfizer Executive to join board

Feb 03, 2005	Neuren lists on ASX

Feb 01, 2005	Annual Report & Financial Statements - y/e 31/12/01

Feb 01, 2005	Annual Report & Financial Statements - y/e 31/12/02

Feb 01, 2005	Annual Report & Financial Statements - y/e 31/12/03

Feb 01, 2005	Annual Report & Financial Statements - y/e 31/12/03

Feb 01, 2005	Annual Report & Financial Statements - p/e 31/12/02

Feb 01, 2005	Half Year Directors' Report & Interim Financial Statements

Feb 01, 2005	Distribution Schedule

Feb 01, 2005	Share Option Plan

Feb 01, 2005	Constitution

Feb 01, 2005	Top 20 shareholders

Feb 01, 2005	Conditions for admission to official list

Feb 01, 2005	Appendix 1A - Application for admission to official list

Feb 01, 2005	Circualar re: Commencement of Official Quotation

Feb 01, 2005	Admission to Official List

Jan 05, 2005	Supplementary Disclosure Document

Jan 05, 2005	Disclosure Document